Cagrilintide + Semaglutide
Amylin analogue paired with a GLP-1 agonist for appetite and weight
In short
- Cagrilintide plus semaglutide — an amylin analogue with a GLP-1 agonist. NEITHER is a growth hormone compound; the library description previously said otherwise and has been corrected.
- This is the ONLY blend in the library whose specific combination has been tested in humans, in the phase 3 REDEFINE programme.
- The two act on genuinely different satiety pathways, so the combination is mechanistically additive rather than redundant.
- REDEFINE reported greater weight reduction than either component alone.
- Not approved as a combination product anywhere as of this review; semaglutide alone is approved, cagrilintide is not.
Structure
A blend of two peptides. See the Cagrilintide and Semaglutide entries for their individual structures.
How it works
Semaglutide activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction.
Cagrilintide is a long-acting amylin analogue. Amylin is co-secreted with insulin and acts on receptors in the area postrema to slow gastric emptying, suppress post-meal glucagon, and promote satiety.
These are separate satiety mechanisms, which is precisely why the combination is developed rather than being a marketing exercise. This is the same logic that makes the GH secretagogue blends coherent, and here it has actually been tested.
What the research shows
The REDEFINE phase 3 programme reported weight reductions in the low-to-mid twenties percent range, exceeding semaglutide alone.
Phase 2 established the additive effect that justified phase 3.
This is the only blend in this library with trial evidence for the combination itself rather than only for its parts.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — CagriSema phase 3 trials | 2.4 mg cagrilintide with 2.4 mg semaglutide, weekly, after titration | subcutaneous | PubMed |
| Human — semaglutide alone, approved label for weight management | Titrated to 2.4 mg weekly | subcutaneous | FDA label |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, mirroring the trial ratio | Escalated toward 2.4 mg of each, weekly | subcutaneous |
A pre-mixed vial fixes the ratio between components at whatever the vendor chose. You can change the total volume you draw, but you cannot change the proportions — so if one component suits you at a different relative amount, a blend cannot express that. Buying components separately costs more vials and buys back that control. Unusually, the 1:1 ratio here matches what the trials used, so a pre-mixed vial is closer to the studied intervention than most blends. What is not equivalent is the material: no approved combination product exists, so grey-market vials have unverified identity and concentration for both components.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Weekly subcutaneous injection with slow titration. Gastrointestinal tolerance is the practical constraint on escalation speed, and the trials titrated over months rather than weeks.
Side effects
Nausea, vomiting, diarrhoea, and constipation dominate, dose-related and worst after each escalation — and more pronounced with the combination than with semaglutide alone, since both components slow gastric emptying.
Serious but uncommon: pancreatitis and gallbladder disease, the latter more likely with rapid weight loss.
Semaglutide carries a boxed warning for thyroid C-cell tumours from rodent data; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.
The amylin class carries a hypoglycaemia consideration when combined with insulin — pramlintide, the approved amylin analogue, has a boxed warning for severe hypoglycaemia with insulin.
Delayed gastric emptying is relevant to anaesthesia and appears in pre-operative guidance.
Combinations
Running components together makes attribution impossible in both directions. If something improves you cannot tell which component did it, and if something goes wrong you cannot tell which one to stop. Blends are convenient and they are also the format that teaches you least about your own response.
This is the one blend where the combination is the studied intervention rather than an assumption, so the attribution objection carries less weight — the trials measured the pair, not the parts.
Adding a third incretin agent on top would duplicate GLP-1 agonism and compound gastrointestinal effects without evidence.
Research status
Genuine phase 2 and phase 3 development by Novo Nordisk, with published results.
This is the only entry in this library where "the blend has been studied" is a true statement.
Legal status
Semaglutide is FDA-approved and prescription-only. Cagrilintide is investigational and not approved anywhere. The combination is not approved as a product as of this review date. Grey-market CagriSema is unapproved material outside any regulated supply chain.
WADA status
Neither component is currently prohibited by WADA. Verify against the live list before competition.
Conclusion
CagriSema is the only blend here with real evidence for the combination itself, targeting two genuinely distinct satiety pathways with phase 3 data behind the pairing.
The gap is regulatory rather than scientific: the science is sound and the product you can buy is not the product they tested.
Sources
Track your own Cagrilintide + Semaglutide protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.